Servier Initiates Phase 2 Study of Gevokizumab in Patients With Diabetic Nephropathy
April 01, 2015 at 08:04 AM EDT
XOMA Corporation (Nasdaq: XOMA), a leader in the discovery and development of therapeutic antibodies, announced today gevokizumab will ...
